Ovarian Cancer Drugs Global Market Report 2024

The ovarian cancer drugs market size has grown rapidly in recent years. It will grow from $4.48 billion in 2023 to $5.16 billion in 2024 at a compound annual growth rate (CAGR) of 15.0%. The historical period's growth can be credited to an increase in the occurrence of ovarian cancer, the emergence of new medications and therapies, elevated government initiatives for the treatment of ovarian cancer, and a rise in healthcare expenditure.

The ovarian cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $8.94 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The anticipated growth in the forecast period is linked to the expanding geriatric population and a rise in pharmaceutical research and development expenditure. Key trends expected during this period include the introduction of antibody-drug conjugates, collaborations and partnerships aimed at enhancing revenues and product offerings, and a strategic focus on implanted drug factories for ovarian cancer.

The increasing prevalence of ovarian cancer is a key driver of growth in the ovarian cancer drugs market. Ovarian cancer ranks as the eighth most commonly diagnosed cancer in women and the 18th most prevalent cancer globally. In 2023, as reported by the American Cancer Society in their Ovarian Cancer Statistics, an estimated 19,710 new cases of cancer and 13,270 related deaths were anticipated in the USA alone. This rise in ovarian cancer incidence worldwide contributes significantly to the expansion of the ovarian cancer drugs market.

Government initiatives and funding aimed at addressing ovarian cancer are expected to further propel the growth of the ovarian cancer drugs market. Government initiatives involve providing financial support to selected entities with projects contributing to the improvement of public services and the economy. Such support plays a crucial role in ovarian cancer research, aiming to enhance the quality of life and survival rates for patients. For instance, in July 2021, the National Cancer Institute, a US-based government agency, allocated a significant sum of 134.7 million US Dollars specifically for ovarian cancer research. Consequently, the support and funding from government initiatives are key factors driving the growth of the ovarian cancer drugs market.

Pharmaceutical companies engaged in drug manufacturing are increasingly embracing innovation, particularly in the development of combination drugs for treating ovarian cancer. Combination drugs, composed of two or more active pharmaceutical ingredients (APIs) consolidated into a single dosage form, are designed to address complex medical conditions. Companies in the ovarian cancer drugs market are actively investing in research and development to create innovative products such as combination drugs. These endeavors aim to reduce manufacturing costs, enhance compliance and efficiency, improve medication concordance, boost profitability, and minimize side effects. Notably, Roche's FDA-approved blockbuster drug Avastin (bevacizumab) is an example of a combination drug, featuring ingredients such as carboplatin and paclitaxel, used for the treatment of advanced-stage (III or IV) ovarian cancer.

Major players in the ovarian cancer drug market are strategically focusing on producing innovative drugs, including antibody-drug conjugates, to drive market revenues. Antibody-drug conjugates (ADCs) represent a biopharmaceutical drug category that combines a monoclonal antibody (mAb) with a cytotoxic drug through a chemical linker. For instance, in November 2022, the US-based biotechnology company ImmunoGen, Inc. introduced Mirvetuximab soravtansine-gynx. This drug targets the overexpressed FRα protein on the surface of many cancer cells, including ovarian cancer cells. The antibody delivers the microtubule inhibitor soravtansine to the cancer cells, disrupting their mitosis and causing cell death. This ADC shows promise as a new treatment for patients with folate receptor alpha-positive, platinum-resistant ovarian cancer. It represents the first ADC approved for this type of cancer and has demonstrated positive outcomes in clinical trials.

In September 2021, the Germany-based biopharmaceutical company Boehringer Ingelheim acquired Abexxa Biologics for an undisclosed amount. This strategic acquisition expands Boehringer Ingelheim's oncology portfolio by incorporating Abexxa's technology and antibody-based drugs for cancer treatment. Abexxa Biologics specializes in the development of cancer drugs, immuno-oncology, and advanced precision medicines for various cancer types, including ovarian cancer drugs.

Major companies operating in the ovarian cancer drugs market report are AstraZeneca PLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Amgen Inc., Bristol-Myers Squibb Company, Clovis Oncology, Pfizer, Inc., Novartis AG, Pharma Mar SA, Vivesto, BDR Pharmaceutical, GLS Pharma, Eisai Co., Ltd., Denovo Biopharma, Jiangsu Hengrui Medicine, BeiGene, Innovent Biologics, Zai Lab , EUSA Pharma, Recordati , NEUCA, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, TZMO, Msd Sanofi, Gilead Sciences , Johnson & Johnson, Merck & Co, AbbVie Inc., Aa Pharma In, Aaladin Superior Cleaning Systems Ltd., Accel Pharma Inc., EMS Pharma, Eurofarma, Neo Química, Mantecorp Farmasa , Abbott Laboratories Bayer , Laboratorio Elea Phoenix , Laboratorios Ac Farma , Teva , Monte Verde, Gador, Spimaco, Tabuk Pharmaceuticals, Jamjoom Pharma, Abcon International L.L.C., Adcan Pharma , Regal Pharmaceuticals Limited.

North America was the largest region in the ovarian cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the global ovarian cancer drugs market share during the forecast period. The regions covered in the ovarian cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ovarian cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Ovarian cancer drugs target different types of tumors, namely epithelial ovarian cancer, germ cell ovarian cancer, and stromal cell ovarian cancer. Epithelial ovarian cancer is the most prevalent type, accounting for 90% of ovarian tumors. This form originates in the epithelial layer that covers the ovary. The diverse categories of drugs for ovarian cancer treatment include alkylating agents, mitotic inhibitors, VEGF/VEGF inhibitors, PARP inhibitors, among others. These drugs are distributed through various channels such as hospital pharmacies, drug stores, and others.

The ovarian cancer drugs market research report is one of a series of new reports that provides ovarian cancer drugs market statistics, including ovarian cancer drugs industry global market size, regional shares, competitors with an ovarian cancer drugs market share, detailed ovarian cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer drugs industry. This ovarian cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ovarian cancer drugs market consists of sales of Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, and Platinol (Cisplatin). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.